Tenderwize
Wróć do wyszukiwania

Open House discount agreements for active substance Mepolizumab, ATC R03DX09

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 187 days left·Open·Supplies
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Mepolizumab, ATC R03DX09

60/100

Ocena szansy

PromisingLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

60 / 100

Złożoność

20 / 100

Czynniki ryzyka

AOK reserves the right to replace these open house contracts with exclusive procurement contracts at any time, terminat...

No estimated value or volume is provided; revenue cannot be estimated.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Strong opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive discount agreements for the active substance Mepolizumab (ATC R03DX09).
  • Contracts are open to all interested pharmaceutical companies under uniform terms.
Pokaż pełne podsumowanie

Open House model for non-exclusive discount agreements on Mepolizumab (ATC R03DX09) offered by AOK Rheinland-Pfalz/Saarland. Any pharmaceutical company with authorized and marketable Mepolizumab products in Germany can join. Contracts run up to 24 months from May 1, 2025 to April 30, 2027, with rolling join dates. The procedure is not subject to EU procurement law despite using a standard notice form. No estimated value is provided.

Ryzyka

AOK reserves the right to replace these open house contracts with exclusive procurement contracts at any time, terminat...

No estimated value or volume is provided; revenue cannot be estimated.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Only authorized and marketable medicinal products in Germany may be supplied.
  • Proof of authorization and marketability required (Lauer-Taxe listing or AMIce database extract).

Certifications

  • For products not yet listed, additional documentation (e.g., approval certificate) must be provided.

Kryteria udzielenia

Lot 1

No award criteria specified. This is an open house model; all eligible companies are accepted without selection.

Zamawiający

Lokalizacja

Eisenberg, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE271900642

Działalność

Health

Części (1)

LOT-0001

Open House discount agreements for active substance Mepolizumab, ATC R03DX09

Non-exclusive discount agreement for Mepolizumab. Any pharmaceutical company meeting eligibility can sign up. Contracts valid until April 30, 2027. The AOK reserves the right to replace these with exclusive contracts during the term.

SuppliesEU fundedElectronic submission

Lokalizacja

Eisenberg, Germany

Czas trwania

Apr 2025 - Apr 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria specified. This is an open house model; all eligible companies are accepted without selection.

Termin

Deadline Feb 28, 2027

Szczegóły zamówienia

Data publikacji
12 Mar 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
165250-2025

Dokumenty (1)

Podobne przetargi